Houlihan Lokey, Inc. (HLI) Q4 2026 Earnings Call Transcript

Houlihan Lokey held its fiscal Q4 and full-year 2026 earnings conference call on May 6, 2026. The excerpt provided is largely introductory and includes standard forward-looking statement disclosures, with no financial results, guidance, or business updates disclosed in the visible text. As presented, the news is routine and unlikely to move the stock materially.

Analysis

This call is less about the headline quarter and more about what the opening boilerplate implies: management is keeping flexibility high in a market where advisory activity can re-price quickly around deal confidence, rate expectations, and board risk appetite. For an M&A intermediary like HLI, the key second-order effect is leverage to transaction thawing before it shows up in broader market data; the earnings power inflects earlier than underwriting or capital-markets proxies, so the stock can re-rate on forward guidance before reported fee growth accelerates.

The competitive angle matters because HLI sits in the sweet spot between bulge-bracket coverage and boutique specialization. If deal flow re-accelerates, the biggest winners are the firms with reputation-driven win rates and low balance-sheet dependence; that tends to favor HLI over GS and MS in a cleaner fee rebound, while DB remains a lower-quality read-through because its advisory mix is more tied to broader franchise volatility. The second-order effect is that a pickup in restructuring can offset weak announced M&A, but that mix usually supports revenue with lower sensitivity to closing fees and can change near-term margin optics.

The market is likely underappreciating timing dispersion: advisory volumes can improve in waves within one or two quarters, but compensation leverage lags, so the best equity setup is often during the lag between headline stabilization and visible earnings revision. The main risk is that a shallow M&A recovery gets overwhelmed by a still-high rate of withdrawn or delayed processes, leaving consensus too eager on FY27 EPS revisions. In that case, HLI still screens as a quality compounder, but the multiple expansion case stalls until fee visibility extends beyond a single quarter.

Contrarian take: the consensus may focus too much on whether M&A is ‘back’ and not enough on share shift. In a muted environment, firms with strong middle-market brand and restructuring credibility can quietly take wallet share from larger platforms whose coverage economics are less efficient. That makes HLI a better relative long than an outright beta bet on financials, especially if the next catalyst is management signaling sustained pipeline conversion rather than just normalized activity.

Key Decisions for Investors

• Go long HLI vs. GS/MS in a relative-value pair for the next 1-2 quarters; thesis is that HLI should outperform on any incremental M&A stabilization because its earnings are more directly tied to fee rebound and less to balance-sheet/market-making noise.
• Use HLI as a catalyst-driven long into the next management update or interim deal-activity data; entry is best on post-earnings weakness if guidance is merely in-line, with upside from FY27 estimate revisions over the following 60-90 days.
• Avoid chasing DB on a broad advisory recovery trade; if anything, keep DB as a hedge against a false-start M&A rebound because weaker franchise quality makes its earnings less levered to pure advisory improvement.